Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

4662 - Two-step microarray analysis of cell-free miRNA in plasma of lung cancer patients

Date

11 Sep 2017

Session

Poster display session

Presenters

Ivan Zaporozhchenko

Citation

Annals of Oncology (2017) 28 (suppl_5): v1-v21. 10.1093/annonc/mdx361

Authors

I. Zaporozhchenko1, E. Morozkin1, A. Ponomaryova2, E. Rykova1, N. Cherdyntseva2, V. Vlassov3, P. Laktionov3

Author affiliations

  • 1 Laboratory Of Molecular Medicine, Institute of Chemical Biology and Fundamental Medicine SB RAS, 630090 - Novosibirsk/RU
  • 2 Laboratory Of Molecular Oncology And Immunology, Tomsk Cancer Research Institute RAMS, Tomsk/RU
  • 3 Directorate, Institute of Chemical Biology and Fundamental Medicine SB RAS, 630090 - Novosibirsk/RU
More

Resources

Abstract 4662

Background

Lung cancer (LC) is causing more than 1.3 million deaths worldwide annually. Early detection of LC is critical for survival but despite recent advancements in LC diagnostics most patients are still diagnosed at advanced stages of the disease. The situation is further complicated by high intratumor heterogeneity and general diversity of lung malignancies. Insights into cancer genetics have kindled interest in molecular cancer diagnostics. One of the lucrative sources of prospective LC biomarkers is cell-free circulating miRNAs. These small non-coding RNAs are frequently deregulated in LC. It is also known that miRNAs can travel in bodily fluids for extended periods of time, shielded from degradation by membrane vesicles or other biopolymers. Recently, specific subsets of miRNAs associated with tumor phenotypes and disease progression have been found circulating in blood of cancer patients and suggested as potential biomarkers for LC.

Methods

In the present study, we have investigated the profiles of circulating miRNAs in blood plasma of LC patients and healthy individuals (HD) in order to identify potential markers for lung cancer diagnostics. Small RNAs were isolated from blood plasma of 20 LC patients and 10 healthy individuals (HD) using protocol reported earlier (Zaporozhchenko et al, Anal Biochem, 2015). Profiles of miRNA expression were obtained using miRCURY LNA miRNA qPCR Panels Plasma/Serum (Exiqon). Ratio based normalization was applied to all miRNA’s with call rate higher than 80%.

Results

Statistical comparison using two-way ANOVA identified 241 ratios (98 individual miRNAs) with significantly different expression between LC patients and HD (p 

Conclusions

Based on expression in both data sets 5 ratios containing 7 miRNAs were selected for further validation in an extended cohort of LC and cancer-free individuals.

Clinical trial identification

Legal entity responsible for the study

Laboratory of Molecular Medicine, SB RAS Institute of Chemical Biology and Fundamental Medicine, Novosibirsk, Russian Federation

Funding

Study has been supported by Russian Foundation for Basic Research (RFBR, grant No. 14-04-01881), BOR grant VI.62.1.4, and Presidium of RAS research program ‘Molecular and Cellular Biology’ No. 6.1.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.